peptide wiki

Mechanism

Pre-mixed three-peptide blend aimed at stimulating the growth-hormone axis, combining two GHRH analogs (tesamorelin and CJC-1295) with a selective ghrelin-receptor agonist / GH secretagogue (ipamorelin) to drive pulsatile pituitary GH release. Tesamorelin is FDA-approved only as Egrifta for HIV-associated lipodystrophy; CJC-1295 and ipamorelin have no FDA-approved human indication and are grey-market research compounds. This specific three-way combination is not an approved product and has no published controlled human efficacy or safety data, so its rationale is inferred from the individual components rather than from any trial of the blend itself.

Studied uses

• Marketed (research only) for increasing endogenous growth hormone and IGF-1
• Claimed body-composition, recovery and anti-aging effects
• Used off-label/research for lean-mass and fat-loss support

Identification

Typical dose	No validated blend protocol exists. Component vendor norms: tesamorelin ~1–2 mg/day subcutaneous; CJC-1295 (no DAC) ~100 mcg per dose; ipamorelin ~100–300 mcg per dose, typically dosed before bed and/or post-exercise. Research use only.
Half-life	Component-dependent. Tesamorelin: ~26–38 minutes (subcutaneous); CJC-1295 without DAC: ~30 minutes; ipamorelin: ~2 hours. The mixture's combined pharmacokinetics are not characterized.

Safety

Not FDA-approved as a blend; only tesamorelin is approved (Egrifta, for a narrow HIV indication) while CJC-1295 and ipamorelin are grey-market. WADA-PROHIBITED: all three peptides fall under Prohibited List class S2 (peptide hormones, growth factors and mimetics) and are banned in and out of competition. GH-axis stimulation carries risks including insulin resistance, fluid retention, joint pain and potential stimulation of occult tumor growth. No combination-specific human safety data exists.